Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ligand Binding Sites02:40

Ligand Binding Sites

14.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
14.9K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

5.5K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.5K
Enzyme Inhibition01:30

Enzyme Inhibition

91.6K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.6K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.1K
The Two-State Receptor Model01:29

The Two-State Receptor Model

3.0K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
3.0K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the Efficacy of the Canadian Association of Radiologists' Medical Student Network Mock Interview Program for Canadian Medical Students Applying to Diagnostic Radiology.

Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes·2026
Same author

Ultra-Early Mobilization After Split-Thickness Skin Grafting in Burn Patients Is Not Associated with Graft Loss.

Journal of burn care & research : official publication of the American Burn Association·2026
Same author

Consumption of Fructose-Containing Food and Beverage Sources in Childhood Through to Adulthood and Risk of Hypertension: A Prospective Cohort Study.

Circulation·2026
Same author

Revisiting the two-factor model of ethnic-racial and U.S. identity exploration among Hispanic college students.

Cultural diversity & ethnic minority psychology·2026
Same author

Correction to "Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures".

ACS pharmacology & translational science·2026
Same author

Correction to "SH2<i>scan</i>: Mapping SH2 Domain-Ligand Binding Selectivity for Inhibitors and Degraders".

Journal of medicinal chemistry·2026

Related Experiment Video

Updated: Jan 18, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.6K

SH2scan: Mapping SH2 Domain-Ligand Binding Selectivity for Inhibitors and Degraders.

Luis M Gonzalez Lira1, Jennifer K Wolfe-Demarco1, Alexander M Clifford1

  • 1Eurofins DiscoverX, LLC, 11180 Roselle Street, Suite D, San Diego, California 92121, United States.

Journal of Medicinal Chemistry
|January 16, 2026
PubMed
Summary

A new assay, SH2scan, enables high-throughput evaluation of synthetic ligand selectivity for SH2 domains. This advances drug discovery by improving compound design and reducing off-target effects for protein-protein interaction targets.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.2K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.8K

Related Experiment Videos

Last Updated: Jan 18, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.6K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.2K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.8K

Area of Science:

  • Biochemistry and Molecular Biology
  • Drug Discovery and Development

Background:

  • Targeting SH2 domains, crucial for protein-protein interactions, is vital but hindered by a lack of assays for synthetic ligand binding selectivity.
  • Understanding molecular determinants of synthetic ligand engagement across SH2 domains is essential for reducing off-target effects in drug discovery.

Purpose of the Study:

  • To develop a high-throughput assay platform, SH2scan, for quantifying synthetic ligand interactions with SH2 domains.
  • To assess the binding selectivity profiles and dissociation constants (KD) of existing synthetic ligands against a broad range of SH2 domains.

Main Methods:

  • Development of SH2scan, a high-throughput competition binding assay.
  • Quantification of ligand-SH2 domain interactions for over 80% of the SH2 domain target class.
  • Analysis of binding selectivity and dissociation constants for 9 synthetic ligands.

Main Results:

  • SH2scan successfully quantified interactions for >80% of the SH2 domain target class.
  • Unique binding selectivity profiles were uncovered for 9 synthetic SH2 domain ligands.
  • A wide range of dissociation constants (KD) were determined for these ligands.

Conclusions:

  • SH2scan is a valuable platform for designing more selective SH2 domain-targeting compounds.
  • The assay facilitates the discovery of novel molecular probes for dissecting cellular protein-protein interaction networks.
  • This work addresses a critical gap in SH2 domain-focused drug discovery and molecular probe development.